Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN versus VEETIDS 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN versus VEETIDS 125.
BICILLIN vs VEETIDS '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzathine penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin inhibition, leading to cell lysis.
VEETIDS '125' (presumed to be a formulation containing penicillin V potassium) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Benzathine penicillin G 1.2 million units intramuscularly once for early syphilis; 2.4 million units intramuscularly weekly for 3 weeks for late latent syphilis.
125 mg orally twice daily for 5-10 days.
None Documented
None Documented
Terminal elimination half-life: 0.5–1 hour (prolonged in renal impairment); clinical context: requires probenecid for extended action
2-4 hours in patients with normal renal function (CrCl >80 mL/min); prolonged to 20-40 hours in anuria. Clinical note: dosing interval must be adjusted based on creatinine clearance to avoid accumulation.
Primarily renal (60–70% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic